PT  - JOURNAL ARTICLE
AU  - Alhudiri, Inas
AU  - Ramadan, Ahmad M.
AU  - Ibrahim, Khaled M
AU  - Eljilani, Mouna
AU  - Aboud, Adel Abdalla
AU  - Salem, Mohamed Ali
AU  - Elgheriani, Hajer Mohamed
AU  - Elzagheid, Adam
TI  - Whole-genome sequencing of SARS-COV-2 reveals a substantially lower frequency of the UK variant than previously announced in Libya
AID  - 10.1101/2021.07.03.21257942
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.07.03.21257942
4099  - http://medrxiv.org/content/early/2021/07/06/2021.07.03.21257942.short
4100  - http://medrxiv.org/content/early/2021/07/06/2021.07.03.21257942.full
AB  - A cluster-5 variant was detected in September 2020 in minks and humans in Denmark and currently classified as Alpha or B.1.1.7 strain. This variant presents several mutations in the spike region (S) which could increase the transmissibility of the virus 43-90% over previously circulating variants. The national center for disease control (NCDC) announced on 24th February 2021 the discovery of B.1.1.7 strain in Libya using a reverse-transcriptase PCR assay for S-gene target failure (SGTF) and reported that 25% of the tested samples were UK variant. This assay relies on the specific identification of the H69-V70 deletion in S gene which causes S gene drop out in RT-PCR; characteristic of the UK variant (B.1.1.7). This letter discusses our whole genome sequencing results of positive SARS-COV-2 samples with SGTF collected between 25th February -4th March 2021 in Libya.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors gratefully acknowledge the support of the Libyan authority for research, science and technology, ministry of higher education, ministry of health and the Libyan embassy in Spain as well as all COVID-19 detection team at Biotechnology Research Center.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Biotechnology Research Center Bioethics Committee.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSARS-COV-2 sequencing data are publicly available via the link provided. https://www.ncbi.nlm.nih.gov/nuccore/?term=BTRC+Libya